
Hearing Loss and Antiretroviral Therapy in Patients Infected With HIV-1
Christina M. Marra, MD;
Hope A. Wechkin;
W. T. Longstreth, Jr, MD;
Thomas S. Rees, PhD;
Connie L. Syapin, PhD;
George A. Gates, MD
Arch Neurol. 1997;54(4):407-410.
Abstract
Objective To explore the association between hearing loss and antiretroviral therapy in human immunodeficiency virus type 1 (HIV-1)-infected persons.
Design Case-control study.
Setting University-based HIV clinic.
Participants Volunteer sample of 99 HIV-infected patients.
Interventions Standardized interview focusing on risks for hearing loss, review of clinic pharmacy records, and hearing tests by portable audiometry.
Main Outcome Measure Hearing loss, defined as threshold of more than a 25-dB hearing level at 4000 Hz in 1 or both ears.
Results Hearing loss was common, seen in 29 subjects (29%). It was significantly associated with age and history of ear infection and tended to be more common in subjects prescribed antiretroviral agents. An interaction existed between age and antiretroviral therapy; the association between hearing loss and antiretroviral therapy was significant for subjects aged 35 years or older, but not for subjects younger than 35 years. In subjects aged 35 years or older, this association remained significant using a multivariate model that included those variables found to have the greatest potential for confounding (odds ratio, 4.6; 95% confidence interval, 1.0-20.5; P=.05).
Conclusions Hearing loss is common among HIV-infected individuals and is associated with antiretroviral therapy in those aged 35 years or older.
Author Affiliations
From the Departments of Neurology (Drs Marra and Longstreth and Ms Wechkin), Medicine (Infectious Diseases) (Dr Marra), Epidemiology (Drs Longstreth and Gates), and Otolaryngology-Head and Neck Surgery (Drs Rees, Syapin, and Gates), University of Washington, Seattle.
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
High Prevalence of Hearing Impairment in HIV-Infected Peruvian Children
Chao et al.
Otolaryngol Head Neck Surg 2012;146:259-265.
ABSTRACT
| FULL TEXT
Severe Ototoxicity in a Health Care Worker Who Received Postexposure Prophylaxis with Stavudine, Lamivudine, and Nevirapine after Occupational Exposure to HIV
Rey et al.
Clinical Infectious Diseases 2002;34:418-419.
FULL TEXT
Ototoxicity Associated with Use of Nucleoside Analog Reverse Transcriptase Inhibitors: A Report of 3 Possible Cases and Review of the Literature
Simdon et al.
Clinical Infectious Diseases 2001;32:1623-1627.
ABSTRACT
| FULL TEXT
|